BIO Adopts Principles on Workplace Development, Diversity, and Inclusion; Launches Board WDDI Committee

WASHINGTON–(BUSINESS WIRE)–Today, the Biotechnology Innovation Organization (BIO) released a set of
principles on workforce development, diversity, and inclusion (WDDI) for
the biotechnology industry. Concurrent with the adoption of these
principles, BIO established a board-level WDDI Committee charged with
working to foster workforce development, diversity, and inclusion at BIO
and throughout the biotech industry. The Committee will be chaired by
Helen Torley, President & CEO of Halozyme, who is succeeding Julie
Gerberding, Executive Vice President & Chief Patient Officer at Merck,
who led the Committee as it developed BIO’s WDDI principles over the
last year.

“As a leader of the 21st century innovation economy, it is
critical that the biotech industry also be at the forefront of efforts
to develop an effective, diverse and talented global workforce,” said
BIO President & CEO Jim Greenwood. “BIO is proud to announce the
formation of the WDDI Committee, which will lead our efforts to attract
the best and brightest talents from diverse backgrounds to biotech
careers, foster an inclusive industry culture, and, most importantly,
enable biotech companies and their employees to understand, interact
with, and ultimately provide treatment to a diverse patient population
with the cultural competency required for success.”

The principles on WDDI adopted today by BIO’s Board of Directors state
that BIO considers diversity to be essential to the success of the
biotechnology industry. BIO commits itself to, and encourages the
industry to follow, these principles on workforce development,
diversity, and inclusion:

     
1. BIO believes that our members’ products and services should be
intended to address the needs of a diverse population.
 
2. BIO believes that diversity in all aspects of business operations
will optimize the continued growth and success of the biotechnology
industry.
 
3. BIO will champion workforce development, diversity and inclusion as
a way to attract, develop and retain the employee talent pool within
the globally competitive biotechnology industry.
 
4. BIO will lead by example and be outward-facing in our diversity
efforts, and will incorporate diversity and inclusion into all
aspects of BIO operations: in communications and membership
engagement, at BIO events through programming and education, and in
the composition of the Board of Directors and its committees.
 
5. BIO will engage with external partners to broaden the reach and
incorporation of diversity throughout the biotechnology ecosystem.
 
6. Definitions. For purposes of these Principles, the following terms
shall have the meanings set forth below:
 

 

   

a.

  Diversity is defined as the wide-range of similarities and
differences among persons and perspectives, and follows guidelines
established by the U.S. Equal Employment Opportunity Commission.
 

 

b.

Inclusion is defined as the process of creating a business culture
and environment that recognizes and effectively leverages the
talents, skills, and perspectives of diverse employees.
 

 

c.

Workforce development is defined as the process of ensuring all
employees have the opportunities to develop the capabilities and
skills required to meet the challenging needs in the biotechnology
industry.
 

“Adopting these principles is an important first step in BIO’s work to
ensure that the biotechnology industry is an employer of choice for
talented individuals from all backgrounds,” said Julie Gerberding,
Executive Vice President and Chief Patient Officer at Merck. “This week,
the BIO International Convention will showcase the breadth and depth of
talent our industry has to offer, and the Convention programming
reflects that diversity. Going forward under Helen’s leadership, the
Committee will work with professionals within the biotech industry, BIO
staff, and partner organizations to fulfill our mission to create a more
globally competitive biotechnology industry by promoting and enhancing
workforce development, diversity, and inclusion.”

The 2017 BIO International Convention features three panels on the
importance of WDDI in the biotechnology industry:

  • Invest in Diversity to Drive Innovation – Wednesday, June 21 at
    10:45 am
  • An Issue Not to be Ignored: Diversity in Clinical Trials
    Wednesday, June 21 at 1:45 pm
  • Career and Personal Paths to the Corporate Boardroom, presented by
    Women in Bio
    – Thursday, June 22 at 11:00 am

To learn more about BIO’s WDDI efforts, visit bio.org/diversity.

About BIO

BIO is the world’s largest trade association representing biotechnology
companies, academic institutions, state biotechnology centers and
related organizations across the United States and in more than 30 other
nations. BIO members are involved in the research and development of
innovative healthcare, agricultural, industrial and environmental
biotechnology products. BIO also produces the BIO
International Convention
, the world’s largest gathering of the
biotechnology industry, along with industry-leading investor and
partnering meetings held around the world. BIOtechNOW
is BIO’s blog chronicling “innovations transforming our world” and the
BIO Newsletter is the organization’s bi-weekly email newsletter. Subscribe
to the BIO Newsletter
.

 

Upcoming BIO Events

 

BIO
International Convention

June 19-22, 2017
San Diego, CA

       

BIO
World Congress on Industrial Biotechnology

July 23-26, 2017
Montreal, Canada

 

BIO
Patient and Health Advocacy Summit

October 2-3, 2017
Washington,
DC

BIO
Investor Forum

October 17-18, 2017
San Francisco, CA

 

Contacts

Biotechnology Innovation Organization
Daniel
Seaton
, 202-470-5207
Web: www.bio.org
Blog:
www.biotech-now.org
Twitter:
@IAmBiotech